Kazushi Yoshida

Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients

Akira Inoue, Kazushi Yoshida, Satoshi Morita et al. · Japanese Journal of Clinical Oncology · 2016 · 68 citations · Full text

Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression

Yoshitaka Seki, Yutaka Fujiwara, Takashi Kohno et al. · ESMO Open · 2018 · 21 citations · Full text

Pathology, Extrathoracic Disease Progression, Egfr Mutations +20

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring EGFR mutations (JO25567): an open-label, randomized, multicenter, phase II study.

Kazushi Yoshida, Yasuhide Yamada · PubMed · 2015 · 19 citations · Full text

First-line Therapy, Immunology, Pathology +17

Inter- and intra-tumor heterogeneity of genetic and immune profiles in inherited renal cell carcinoma

Mariko Tabata, Yusuke Sato, Yasunori Kogure et al. · Cell Reports · 2023 · 18 citations · Full text

Engineering, Immunology, Pathology +18